Jul. 27 at 1:05 PM
$IMUX A very important paper published in Science Translational Medicine adds more evidence that EBV plays a central role in MS.
The study found that untreated MS patients had about 2x stronger EBV-specific CD4+ T-cell responses than healthy controls, with the immune response mainly directed against late lytic EBV antigens. Anti-CD20 therapy reduced these responses and eliminated detectable EBV shedding.
This doesn’t prove vidofludimus calcium works, but it does strengthen the scientific rationale behind EBV-targeted approaches in MS. If Phase 3 is successful, this type of research could become even more relevant.
